Aurinia Pharmaceuticals Inc at Cantor Fitzgerald Global Healthcare Conference (Virtual) Transcript
Alethia Young here. I cover large-cap, small mid-cap biotech at Cantor. I'm very happy to have Aurinia here with us. I have Peter Greenleaf, who is the CEO of the company. And we're doing a fireside chat for almost all of this.
Questions & Answers
And why don't I just start off, Peter, with you kind of framing, I mean you have your first drug approved on the market. So just tell us a little bit about how the past 12 months has been going.
Yes. So just to start, for folks that may not know the company, we are -- the company has been around for about 10 years. And it was a development-stage company up until about -- just about 1.5 years ago, where we produced data in the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
